Physician profile
Eric D Greenberg
NPI 1689812489
$7,934.84
in general payments reported to CMS, 2019-2025
39 companies · $1,227 in 2025
The $1,227 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $797 · 2021: $1,441 · 2022: $1,373 · 2023: $886 · 2024: $1,243 · 2025: $1,227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,341 · Consulting Fee: $15.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,340.54 |
| Consulting Fee | $15.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,404.42 | 2019-2024 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals LP | $928.36 | 2019-2025 | Farxiga, Brilinta, Wainua |
| Merck Sharp & Dohme LLC | $845.27 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $746.04 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $539.46 | 2019-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $433.89 | 2021-2025 | Jardiance |
| Pfizer INC. | $274.45 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $252.31 | 2020-2025 | Onpattro, Amvuttra |
| Esperion Therapeutics, INC. | $247.90 | 2020-2025 | Nexletol |
| Abbott Laboratories | $226.20 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| E.R. Squibb & Sons, L.L.C. | $205.85 | 2019-2025 | Camzyos |
| Amarin Pharma, INC. | $200.01 | 2019-2022 | |
| Amgen INC. | $179.16 | 2020-2025 | Repatha, Uplizna, Repatha |
| Kestra Medical Technology Services, INC. | $174.93 | 2023-2025 | Assure Wcd |
| Allergan, INC. | $122.91 | 2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $118.00 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $102.72 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $93.26 | 2023-2024 | Inpefa |
| Medtronic Vascular, INC. | $91.47 | 2019 | |
| Edwards Lifesciences Corporation | $81.22 | 2021-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Novo Nordisk INC | $71.02 | 2025 | Wegovy |
| Chiesi USA, INC. | $64.50 | 2022-2025 | Kengreal, Cleviprex |
| Actelion Pharmaceuticals US, INC. | $60.63 | 2024-2025 | Opsumit, Uptravi |
| Baxter Healthcare | $58.41 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Heartflow, INC. | $45.35 | 2023 | Ffrct |
| Lantheus Medical Imaging, INC. | $45.33 | 2020-2021 | |
| Depuy Synthes Sales INC. | $44.55 | 2024 | Motoband |
| Sanofi-Aventis U.S. LLC | $38.79 | 2019 | |
| Bridgebio Pharma, INC. | $31.23 | 2025 | Attruby |
| Medtronic, INC. | $30.59 | 2022 | |
| Bardy Diagnostics, INC. | $26.12 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $24.97 | 2023 | Arcalyst |
| Recor Medical INC | $24.18 | 2025 | Paradise Ultrasound Renal Denervation System |
| Tactile Systems Technology INC | $23.82 | 2022 | |
| Abiomed | $20.32 | 2023 | Impella |
| United Therapeutics Corporation | $18.99 | 2022 | |
| Lilly USA, LLC | $14.38 | 2024 | Mounjaro |
| Regeneron Healthcare Solutions, INC. | $12.71 | 2022 | |
| Gilead Sciences, INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Greenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.